Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate Cancer Risk Factors

Prostate Cancer Screening

Prostate Cancer Symptoms

Prostate cancer complications

Prostate Cancer Diagnosis

Prostate Cancer Staging

Prostate Cancer Treatment

Radiation therapy for prostate cancer

Life after prostate cancer treatment

Prostate cancer prevention

See more featured articles »

Survival rates of prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

Prostate Cancer Epidemiology

Prostate Cancer Research

Prostate Cancer Partin Tables

Prostate Cancer and Genetics

Prostate Cancer and Diet

Rectal Examination for Prostate Cancer

Cryosurgery for prostate cancer

Hormonal therapy for prostate cancer

Prostate cancer alternative and complementary therapies

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

The International Prostate Symptoms Score (IPSS)

Types of PSA Test

What is the PSA Test?

Prostate Biopsy

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Differentiating between prostate cancer and prostate enlargement

Choosing the best treatment of prostate cancer - by stage

What is the PCA3 Test?

What is the Gleason Score?

What is Prostatectomy?

What is Prostatitis?

Causes of prostatitis

Prostatitis symptoms

Diagnosis of prostatitis

Treatment of prostatitis

What is TURP?

What is medical castration?

What is benign prostatic hyperplasia?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Symptoms of Benign Prostatic Hyperplasia (BHP)

Causes of benign prostatic hyperplasia

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer and Exercise

Prostate Cancer Epidemiology Worldwide

Prostate Cancer Cell Dormancy and Activation

Single Nucleotide Polymorphisms and Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Brachytherapy for Prostate Cancer

What Should You Avoid Before a PSA Test?

Latest Prostate Cancer News and Research

Top urologists share their insights and practical tips at "Urology on the Beach"

Desai Sethi Urology Institute brings renowned thought leaders to Miami Beach. From urologic cancers to female urology to male infertility to kidney stones and sexual health, top urologists from throughout the nation shared their insights and practical tips at "Urology on the Beach," a conference hosted January 13-15 by the Desai Sethi Urology Institute at the University of Miami Miller School of Medicine.

27 Jan 2023

Cryo-electron microscopy captures the first 3D structure of SPOP protein that drives cancer

SPOP is the most mutated protein in prostate cancer and plays a role in endometrial, uterine and other cancers. Despite this importance, how SPOP mutations drive cancer has been incompletely understood.

23 Jan 2023

Cancer mortality in the U.S. has declined 33% since the 90s

The American Cancer Society has recently published the statistics of cancer incidence and mortality for 2023 in CA: A Cancer Journal for Clinicians.

17 Jan 2023

American Cancer Society's annual report on cancer facts and trends released

Today, the American Cancer Society released Cancer Statistics, 2023, the organization's annual report on cancer facts and trends. According to the report, overall cancer mortality has dropped 33% since 1991, averting an estimated 3.8 million cancer deaths.

12 Jan 2023

Hormonal therapy may aid in reducing progression of early-stage prostate cancer during active surveillance

For men with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggests a preliminary clinical trial in The Journal of Urology, an Official Journal of the American Urological Association.

11 Jan 2023

PSMA PET/MRI can successfully determine the risk of prostate cancer recurrence

In men recently diagnosed with intermediate or high-grade prostate cancer, prostate specific membrane antigen (PSMA) PET/MRI can successfully determine whether their cancer is likely to return within two years of a prostatectomy.

6 Jan 2023

Study shows the prevalence of low-value prostate cancer screening in primary care clinics

Prostate cancer is the second-leading cause of cancer death in men with more than 34,000 deaths in the U.S. each year, according to the American Cancer Society.

4 Jan 2023

Weighing risks of a major surgery: 7 questions older Americans should ask their surgeon

Larry McMahon, who turns 80 this month, is weighing whether to undergo a major surgery. Over the past five years, his back pain has intensified. Physical therapy, muscle relaxants, and injections aren't offering relief.

3 Jan 2023

UTSW researchers identify molecular function of 87 inherited genetic variants linked to prostate cancer

UT Southwestern researchers have identified the molecular function of 87 inherited genetic variants that affect the risk of prostate cancer, and the majority appear to control the activity of genes located far away from the risk variants themselves.

23 Dec 2022

New method combines injectable radioactive gel with systemic chemotherapy to treat pancreatic cancer

Pancreatic cancer is one of the deadliest types of cancer-;in the U.S., it is estimated that over 88 percent of people will die from the disease within five years of their diagnosis.

20 Dec 2022

Rising Medicare costs linked to increased use of new prostate cancer therapies

Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years – reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice, an Official Journal of the American Urological Association.

20 Dec 2022

BGI cares - 2022 social responsibilities in review

At BGI Genomics, we believe it is our responsibility to not only enhance global health outcomes, but also to help make the places we work and live in better.

From BGI Genomics 20 Dec 2022

Imaging method yields highly accurate and precise values of radionuclide organ uptake

Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation therapy that is delivered into or very close to the tumor.

16 Dec 2022

Genetic testing program could help to close the gap for some patients with prostate cancer

Some patients with prostate cancer have genetic mutations that may impact their treatment. A comprehensive, on-site genetic testing program, pioneered by urologists, could help to close the gap for this underutilized resource, reports a study in Urology Practice®, an Official Journal of the American Urological Association (AUA).

15 Dec 2022

Exercise has many benefits even for people with advanced cancer

It is well-known exercise has many benefits, but new Edith Cowan University (ECU) research has revealed just how critically important it can be – even for people with advanced cancer.

15 Dec 2022

Two Cents' Worth: Shared decision making in renal cell carcinoma (RCC)

In this interview, we speak to Steve Pointon, patient advocate in remission from RCC, and Dr Harm van Melick, Consultant Urologist, about their experiences with shared decision-making and the impact it can have on people living with renal cell carcinoma (RCC).

From Ipsen 15 Dec 2022

Expansion of intermediate cells in prostate cancer correlates with treatment resistance and poor outcomes

Researchers have characterised prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease – from its beginning to the point of androgen independence, where the tumour no longer responds to hormone deprivation therapy.

14 Dec 2022

Cambridge scientists develop a comprehensive tool for predicting individual's risk of prostate cancer

Cambridge scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer, which they say could help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk.

12 Dec 2022

Discovery of cellular uptake pathway for larger molecules can be harnessed to create new drugs

A fundamental challenge in drug development is the balance between optimizing a drug's lock-and-key fit with its target and the drug's ability to make its way across the cellular membrane and access that target.

8 Dec 2022

New project aims to address the vast data-related problems in cancer research

The National Cancer Institute has awarded $10.5 million to the Division of Biostatistics at the Department of Population and Public Health Sciences at the Keck School of Medicine of USC.

6 Dec 2022